CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 63 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $549,438 | -52.2% | 425,921 | -36.2% | 0.00% | -50.0% |
| Q2 2023 | $1,149,015 | +13.9% | 668,032 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,008,728 | +68802.2% | 668,032 | -27.0% | 0.00% | -20.0% |
| Q4 2022 | $1,464 | -99.9% | 914,900 | -14.1% | 0.01% | -16.7% |
| Q3 2022 | $1,545,000 | +995.7% | 1,065,392 | +3735.9% | 0.01% | – |
| Q3 2021 | $141,000 | -95.5% | 27,774 | -94.4% | 0.00% | -100.0% |
| Q2 2021 | $3,121,000 | +97.8% | 493,013 | +141.5% | 0.01% | +83.3% |
| Q1 2021 | $1,578,000 | +10.1% | 204,141 | -6.7% | 0.01% | 0.0% |
| Q4 2020 | $1,433,000 | +24.6% | 218,763 | +26.5% | 0.01% | 0.0% |
| Q3 2020 | $1,150,000 | -45.6% | 172,876 | -31.9% | 0.01% | -57.1% |
| Q2 2020 | $2,113,000 | +13.2% | 253,700 | +12.9% | 0.01% | +16.7% |
| Q4 2019 | $1,867,000 | +233.4% | 224,640 | +196.0% | 0.01% | +200.0% |
| Q3 2019 | $560,000 | -59.9% | 75,900 | -39.0% | 0.00% | -60.0% |
| Q2 2019 | $1,396,000 | +284.6% | 124,400 | +533.5% | 0.01% | +150.0% |
| Q3 2018 | $363,000 | – | 19,638 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,576,471 | $36,526,000 | 1.44% |
| Altium Capital Management LP | 273,703 | $1,793,000 | 0.67% |
| Jackson Creek Investment Advisors LLC | 80,367 | $526,000 | 0.21% |
| HARBOURVEST PARTNERS LLC | 79,193 | $519,000 | 0.20% |
| XTX MARKETS LLC | 14,169 | $93,000 | 0.19% |
| Perceptive Advisors | 2,577,043 | $16,880,000 | 0.18% |
| RTW INVESTMENTS, LP | 1,527,352 | $10,004,000 | 0.17% |
| Exane Asset Management | 30,568 | $200,220,000 | 0.14% |
| Virtus ETF Advisers LLC | 37,343 | $245,000 | 0.10% |
| Congress Park Capital LLC | 25,807 | $169,000 | 0.10% |